Fundraising Fox
Castle Creek Biosciences
Exton, US · Founded 2018 · Delaware corporation · 25 employees on LinkedIn · 4 known investors
Find your way into Castle Creek Biosciences
580 people in our graph share verified history with the Castle Creek Biosciences team — schools, employers, funds. One of them is your warm intro.
Kavita Björkdahlunlockedknows Matthew Gantz · together at Swedish Orphan Biovitrum (overlapped)
knows the team · via BTG
knows the team · via Chiron Corporation (now Novartis)
×6knows the team · via United States Marine Corps
×2knows the team · via Hydra Biosciences
knows the team · via Swedish Orphan Biovitrum
Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.
Founders & leadership
MG
Matthew GantzPresident and Chief Executive OfficerHe brings over 20 years of experience leading specialty biopharmaceutical and medical device companies.
MT
Michael Townsley
CJ
Christopher J. LarsonChristopher J. Larson has spent 25+ years in quality control and laboratory operations across cell and gene therapy, biologics, and oncology manufacturing, leading teams of 60+ scientists and scaling laboratory operations from early-stage clinical through commercial production. He previously held positions at SK Pharmteco/CBM and Endo Pharmaceuticals supporting CAR-T, AAV, lentiviral and adenoviral vector programs, and earlier contributed to development of an FDA-cleared circulating tumor cell enumeration assay that generated a US patent and a cited publication.
RW
Rhea WilliamsRhea Williams has spent over 30 years in regulatory affairs and quality assurance across pharmaceutical and biotechnology, including leadership roles in regulatory strategy at biotech companies and founding Secord Inc., a regulatory and quality assurance consulting firm, in 2000. Her experience spans global drug development from small molecules to gene and cell therapies, with particular focus on rare disease and oncology programs, and direct engagement with the FDA, EMA, and other regulatory agencies.
JS
Jude SullivanExecutive
DP
Darien ParhadExecutive
MD
Michael DerbyChief Executive Officer
TC
Timothy CunniffNamed on SEC filing
Board
MC
Matthew CrabtreeBoard director
DB
David BrillBoard director
JA
Jeffrey AroninBoard director
Investors · 4
Paragon Biosciences LLClisted by Paragon Biosciences LLCChicago
How we know: Paragon Biosciences LLC's portfolio page · paragonbiosci.com · Not right? Tell us
Valor Equity Partnerslisted by Valor Equity PartnersChicagovia Antonio Gracias · board
How we know: Valor Equity Partners's portfolio page · board seat on SEC Form D · funding news · paragonbiosci.com · the VCSheet dataset · Not right? Tell us
Fidelity InvestmentsreportedBoston
How we know: funding news · paragonbiosci.com · Not right? Tell us
HorizonreportedMiami Beach
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$839.8M disclosed across 6 rounds · 2018–2025
▶$75MraisedFeb 2025 · 30 investors · BiotechnologyRule 506(b)
▶$75MraisedFeb 2025 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BrillDirector
- Matthew CrabtreeDirector
- Jeffrey AroninDirector
- Matthew GantzExecutive Officer, Director
- Patrick MorrisDirector
- Jude SullivanExecutive Officer
- Darien ParhadExecutive Officer
- Antonio GraciasDirector
- Offering amount
- $75M
- Amount sold
- $75M
- Sales commissions
- $2.8M
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$112.8MraisedMay 2022 · 54 investors · BiotechnologyRule 506(b)
▶$112.8MraisedMay 2022 · 54 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark GrafDirector
- Matthew J. GantzExecutive Officer, Director
- W. Bradford MiddlekauffExecutive Officer
- Mary SpellmanExecutive Officer
- Jeffrey S. AroninDirector
- Patrick J. MorrisDirector
- Antonio GraciasDirector
- Offering amount
- $112.8M
- Amount sold
- $112.8M
- Sales commissions
- $1.7M
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$11.8MraisedFeb 2022 · 6 investors · BiotechnologyRule 506(b)
▶$11.8MraisedFeb 2022 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey S. AroninDirector
- W. Bradford MiddlekauffExecutive Officer
- Matthew J. GantzExecutive Officer, Director
- Mark GrafDirector
- Patrick J. MorrisDirector
- Antonio GraciasDirector
- Babar GhiasExecutive Officer
- Mary SpellmanExecutive Officer
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- Sales commissions
- $625K
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$25MraisedJul 2021 · 36 investors · BiotechnologyRule 506(b)
▶$25MraisedJul 2021 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew J. GantzExecutive Officer, Director
- Mary SpellmanExecutive Officer
- Gregory MacMichaelExecutive Officer
- Gregory WujekExecutive Officer
- Antonio GraciasDirector
- W. Bradford MiddlekauffExecutive Officer
- Patrick J. MorrisExecutive Officer, Director
- Jeffrey S. AroninDirector
- Offering amount
- $25M
- Amount sold
- $25M
- Sales commissions
- $625K
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$54.6MraisedJan 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$54.6MraisedJan 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey S. AroninDirector
- Gregory WujekExecutive Officer, Director
- Patrick J. MorrisExecutive Officer, Director
- Timothy M. CunniffDirector
- Antonio J. GraciasDirector
- Offering amount
- $54.6M
- Amount sold
- $54.6M
- Minimum investment
- $82.4K
- Sales commissions
- $710K
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$560.5MraisedOct 2018 · 19 investors · PharmaceuticalsRule 506(b)
▶$560.5MraisedOct 2018 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey AroninDirector
- Michael DerbyExecutive Officer, Director
- Antonio GraciasDirector
- Patrick MorrisExecutive Officer, Director
- Timothy CunniffDirector
- Offering amount
- $560.5M
- Amount sold
- $560.5M
- Sales commissions
- $1.2M
- Placement agents
- Octagon Capital Group, LLC
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Castle Creek Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Castle Creek Biosciences do?
- Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.
- Who are Castle Creek Biosciences's investors?
- Castle Creek Biosciences's investors include Paragon Biosciences LLC, Valor Equity Partners, Fidelity Investments, Horizon.
- How much funding has Castle Creek Biosciences raised?
- Castle Creek Biosciences has disclosed $839.8M raised across 6 rounds.
- Where is Castle Creek Biosciences headquartered?
- Castle Creek Biosciences is headquartered in Exton, US.